Results 1 to 10 of about 22,744 (213)

Venetoclax as a cytoreduction therapy option for acute promyelocytic leukemia in newly diagnosed adult patients: a case report of a 35-year-old female with schizophrenia [PDF]

Frontiers in Oncology
Venetoclax is effective in treating relapsed acute promyelocytic leukemia (APL), newly diagnosed pediatric APL, variant APL, and APL with central nervous system involvement. In newly diagnosed adult APL, venetoclax is rarely used.
Lingling Wang, Yuqing Miao, Yuexin Cheng
doaj   +2 more sources

The correlation between the extent of left upper abdominal resections and perioperative outcomes in advanced stage and relapsed ovarian cancer [PDF]

Romanian Journal of Medical Practice, 2020
The aim of this study is to analyze the feasibility and safety of left upper abdominal resections as part of debulking surgery. Case series presentation. Between January 2015 and August 2019, 32 patients were submitted to left upper abdominal resections.
Nicolae BACALBASA, Irina BALESCU, Camelia DIACONU, Simona DIMA, Laura ILIESCU, Mihai DIMITRIU, Mihaela VILCU, Alexandru FILIPESCU, Ioana HALMACIU, Dragos CRETOIU, Iulian BREZEAN   +10 more
doaj   +1 more source

The role of quaternary cytoreduction in relapsed ovarian cancer – a systematic review [PDF]

Archives of the Balkan Medical Union, 2020
Introduction. Ovarian cancer is characterized by a high capacity of relapse, even in cases in whom cytoreductive surgery with curative intent followed by platinum and taxanes-based chemotherapy were performed.
Nicolae BACALBASA, Irina BALESCU, Mihaela VILCU, Ioana HALMACIU, Camelia C. DIACONU, Simona DIMA, Iulian BREZEAN   +6 more
doaj   +1 more source

Quaternary and beyond cytoreduction: An updated and expanded analysis

Gynecologic Oncology Reports, 2021
Objective: We sought to describe the clinicopathologic features and outcomes of patients undergoing quaternary, quinary, or senary cytoreductive surgery for ovarian cancer. Methods: We retrospectively identified patients with recurrent epithelial ovarian,
Beryl L. Manning-Geist, Dennis S. Chi, Kara Long Roche, Oliver Zivanovic, Yukio Sonoda, Ginger J. Gardner, Roisin E. O'Cearbhaill, Nadeem R. Abu-Rustum, Mario M. Leitao, Jr.   +8 more
doaj   +1 more source

Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis

Diagnostics, 2023
For women achieving clinical remission after the completion of initial treatment for epithelial ovarian cancer, 80% with advanced-stage disease will develop recurrence.
Faiza Gaba, Oleg Blyuss, Dhivya Chandrasekaran, Nicolò Bizzarri, Basel Refky, Desmond Barton, Thomas Ind, Marielle Nobbenhuis, John Butler, Owen Heath, Arjun Jeyarajah, Elly Brockbank, Alexandra Lawrence, Ranjit Manchanda, James Dilley, Saurabh Phadnis, on behalf of the GO SOAR Collaborative   +16 more
doaj   +1 more source

Extreme Leukocytosis and Gangrenous Cholecystitis Associated with Cytoreductive Surgery and HIPEC-Treated Mucinos Ovary Cancer: Case Report and Literature Review

Clinics and Practice, 2023
Mucinous ovarian cancer occurs sporadically, with a frequency of approximately 3–5% among all subtypes of ovarian cancer. Extreme leukocytosis >40,000 and 50,000 has been described in most solid tumors and is associated with a poor prognosis, although ...
Stojan Latincic, Maja Pavlov, Jovica Vasiljevic, Dragan Vasin, Maja Dimic-Cumic, Marjan Micev, Milena Papovic, Miljan Doskovic, Stefan Bugarin, Stefan Milosevic, Dragutin Kecmanovic   +10 more
doaj   +1 more source

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica, 2022
Introduction The survival benefits of surgical cytoreduction in ovarian cancer are well‐established. However, the surgical outcome has never been assessed while controlling for the efficacy of chemotherapy.
Nicholas Cardillo, Eric Devor, Christian Calma, Silvana Pedra Nobre, Sofia Gabrilovich, David P. Bender, Michael Goodheart, Jesus Gonzalez‐Bosquet   +7 more
doaj   +1 more source

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer

South Asian Journal of Cancer, 2023
Sanjay M. Desai Objectives Epithelial ovarian cancer (EOC) is a heterogeneous, essentially peritoneal disease.
Elroy Saldanha, Sanjay M. Desai, Dhruv G. Patel, Vinod Dhakad, Bonny Joseph, Sandeep Ghosh, Varun Prakash, Harsha Deepti, Ashma Monteiro   +8 more
doaj   +1 more source

A Cohort Study to Decode the Application of Peritoneal Carcinomatosis Index in Predicting the Prognosis of Advanced Ovarian Malignancies [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Peritoneal Carcinomatosis Index (PCI) is used to assess the extent of peritoneal cancer by dividing the peritoneal cavity into 13 well-defined regions and assessing the size of the largest tumour nodule in each region. Aim: To evaluate the
Athul Damodaran, Gopinathan Kathirvelu, Devimeenal Jagannathan   +2 more
doaj   +1 more source

Results of treatment of cancer patients with peritoneal carcinomatosis

Journal of Education, Health and Sport, 2022
Objective: At present, common forms of cancer of different localization can not be ignored. New approaches to the treatment of metastatic lesions have some success in clinical application.
O. Bondar, A. Rybin, A. Varabina
doaj   +1 more source